Download PDF
Exp Clin Endocrinol Diabetes 2007; 115(9): 594-599
DOI: 10.1055/s-2007-981670
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Prevalence of RAS Point Mutations in Papillary Thyroid Carcinoma; A Novel Mutation at Codon 31 of K-RAS

A. Cyniak-Magierska 1 , E. Brzeziańska 1 , J. Januszkiewicz-Caulier 1 , B. Jarząb 2 , A. Lewiński 1
  • 1Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland
  • 2Centre of Oncology - MSC Institute, Gliwice, Poland
Further Information

Publication History

received 19. 07. 2006 first decision 08. 05. 2007

accepted 16. 05. 2007

Publication Date:
18 October 2007 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to assess the incidence of point mutations in RAS oncogenes of papillary thyroid carcinoma (PTC). Tumour specimens were obtained from 29 PTCs. The fragments of exons 1 and 2 of RAS oncogenes family (H-RAS, K-RAS, N-RAS) were amplified and then, point mutations were detected by SSCP and/or by RFLP analysis. Several DNA samples were directly sequenced to confirm the results. Two mutations were found in this study (GAA/CAA at codon 31 of K-RAS and CAA/CAC at codon 61 of N-RAS oncogene). These data confirm the results of previous studies, showing that RAS mutations are more rarely found in PTC than in follicular neoplasms. The influence of a novel mutation at codon 31 of K-RAS oncogene on the development of PTC needs further studies.

Key words

RAS oncogenes - point mutations - papillary thyroid carcinoma

References

  • 1 Lewiński A, Ferenc T, Sporny S, Jarząb B. Thyroid carcinoma: diagnostic and therapeutic approach; genetic background.  Endocr Regul. 2000;  34 99-113
    PubMedGoogle Scholar
  • 2 Frattini M, Ferrario C, Bressan P, Balestra D, Cecco L De, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.  Oncogene. 2004;  23 7436-7440
    CrossrefPubMedGoogle Scholar
  • 3 Liu RT, Hou CY, You HL, Huang CC, Hock-Liew , Chou FF, Wang PW, Cheng JT. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.  Thyroid. 2004;  14 616-621
    CrossrefPubMedGoogle Scholar
  • 4 Bouras M, Bertholn J, Detrieux-Berger N, Parvaz P, Paulin C, Revol A. Variability of H-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.  Eur J Endocrinol. 1998;  139 209-216
    CrossrefPubMedGoogle Scholar
  • 5 Vasko VV, Gaudart J, Allasia C, Savchenko V, Cristofaro J Di, Saji M, Ringel MD, Micco C. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma.  Eur J Endocrinol. 2004;  151 779-786
    CrossrefPubMedGoogle Scholar
  • 6 Hara H, Fulton N, Yashiro T, Ito K, De Groot LJ, Kaplan EL. N-ras mutation: An independent prognostic factor for aggressiveness of papillary thyroid carcinoma.  Surgery. 1994;  116 1010-1016
    PubMedGoogle Scholar
  • 7 Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations.  Am J Clin Pathol. 2003;  120 71-77
    CrossrefPubMedGoogle Scholar
  • 8 Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.  Am J Surg Pathol. 2006;  30 216-222
    CrossrefPubMedGoogle Scholar
  • 9 Cristofaro J Di, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, Micco C De. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.  Hum Pathol. 2006;  37 824-830
    CrossrefPubMedGoogle Scholar
  • 10 Sobin L, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. John Wiley and Sons, Hoboken, New Jersey 2002
    Google Scholar
  • 11 Greene LF, Page DL, Fritz A, Batch M, Haller DG, Morrow M. AJCC Chapter 8: Thyroid. in: American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. 2002 Springer, New York 89-98
    Google Scholar
  • 12 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A labolatory manual. Cold Spring Harbor Laboratory Press 1989 6: 22-34
    Google Scholar
  • 13 Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P. Prevalence of ras mutations in thyroid neoplasia.  Clin Endocrinol (Oxf). 1995;  50 529-535
    PubMedGoogle Scholar
  • 14 Bartolone L, Vermiglio F, Finocchiaro M, Violi M, French D, Pontecorvi A, Trimarchi F, Benvenga S. Thyroid follicular oncogenesis in iodine-deficient and sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene.  J Endocrinol Invest. 1998;  21 680-687
    PubMedGoogle Scholar
  • 15 Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphism using the polymerase chain reaction.  Genomics. 1989;  5 874-879
    CrossrefPubMedGoogle Scholar
  • 16 Karga H, Lee JK, Vickery Jr AL, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms.  J Clin Endocrinol Metab. 1991;  73 732-836
    PubMedGoogle Scholar
  • 17 Salvatore D, Celetti A, Fabien N, Paulin C, Martelli ML, Battaglia C, Califano D, Monaco C, Viglietto G, Sanyoro M, Fusco A. Low frequency of p53 mutations in human thyroid tumors; p53 and ras mutation in two out of fifty-six thyroid tumours.  Eur J Endocrinol. 1996;  134 177-183
    PubMedGoogle Scholar
  • 18 Fenton C, Anderson J, Lukes Y, Welch Dinauer CA, Tuttle RM, Francis GL. Ras mutations are uncommon in sporadic thyroid cancer in children and young adults.  J Endocrinol Invest. 1999;  22 781-789
    PubMedGoogle Scholar
  • 19 Suarez HG, Villard JA Du, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R. Presence of mutations in all three ras genes in human thyroid tumors.  Oncogene. 1990;  5 565-570
    PubMedGoogle Scholar
  • 20 Challeton C, Bounacer A, Villard JA, Cailou B, Vathaire F De, Monier R, Schlumberger M, Suarez HG. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors.  Oncogene. 1995;  11 601-603
    PubMedGoogle Scholar
  • 21 Vasko V, Ferrand M, Cristofaro J, Carayon P, Henry JF, Micco C De. Specific pattern of RAS oncogene mutations in follicular thyroid tumors.  J Clin Endocrinol Metab. 2003;  88 2745-2752
    CrossrefPubMedGoogle Scholar
  • 22 Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Carcangiu ML, Costa J, Tallini G. RAS mutations are associated with aggressive tumor phenotype and poor prognosis in thyroid cancer.  J Clin Oncol. 2003;  21 3226-3235
    CrossrefPubMedGoogle Scholar
  • 23 Goretzki PE, Lyons J, Stacy-Phipps S, Rosenau W, Demeure M, Clark OH, Mac Cormick F, Röher HD, Bourne HR. Mutational activation of ras and GSP oncogenes in differentiated thyroid cancer and their biological implications.  World J Surg. 1992;  16 576-582
    PubMedGoogle Scholar
  • 24 Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan.  Br J Cancer. 1998;  77 1060-1065
    PubMedGoogle Scholar
  • 25 Shirouzu MS, Fujita-Yoshigaki J, Ito Y, Koide H, Nishimura S, Yokoyama S. A glutamic acid residue at position 31 of ras protein is essential to the signal transduction for neurite outgrowth of PC12 cells and the stimulation of GTPase activity by GAPras.  Oncogene. 1992;  7 475-480
    PubMedGoogle Scholar
  • 26 Lin SR, Hsu CH, Tsai JH, Wang JY, Hsieh TJ, Wu CH. Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours.  Br J Cancer. 2000;  82 1035-1040
    CrossrefPubMedGoogle Scholar
  • 27 Krohn K, Reske A, Ackermann F, Müller A, Paschke R. RAS mutations are rare in solitary cold and toxic thyroid nodules.  Clin Endocrinol (Oxf). 2001;  55 241-248
    CrossrefPubMedGoogle Scholar
  • 28 Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid.  Oncogene. 2003;  22 6455-6457
    CrossrefPubMedGoogle Scholar
  • 29 Krohn K, Paschke R. BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules.  Thyroid. 2004;  14 359-361
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Brzeziańska E, Pastuszak-Lewandoska D, Migdalska-Sežk M, Wojciechowska K, Lewiński J, Lewiński A. Incidence assessment of BRAF V599E mutation in papillary thyroid carcinoma in Polish population.  (Abstract) Endokrynol Pol. 2005;  56 560-561
    PubMedGoogle Scholar
  • 31 Brzeziańska E, Karbownik M, Migdalska-Sežk M, Pastuszak-Lewandoska D, Włoch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.  Mutat Res. 2006;  599 26-35
    PubMedGoogle Scholar
  • 32 Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.  Cancer Res. 2003;  63 1454-1457
    PubMedGoogle Scholar

Correspondence

Prof. A. Lewiński

Department of Endocrinology and Metabolic Diseases

Medical University of Lodz Polish Mother's Memorial Hospital - Research Institute

Rzgowska St. No. 281/289

93-338 Lodz

Poland

Phone: +48/42/271 13 43

Fax: +48/42/271 13 43

Email: alewin@csk.umed.lodz.pl

      >